Sponsor content

Enzyme engineering for rare genetic diseases and cancer

Aeglea BioTherapeutics is engineering human enzymes for the treatment of both rare genetic diseases and cancer.

0
0
Upvote 0 Comment
Page of
Go to the profile of Aeglea Biotherapeutics

Aeglea Biotherapeutics

Aeglea BioTherapeutics was founded in December 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. The convergence of discovery and technology has created a significant opportunity for Aeglea to potentially impact both the treatment of inborn errors of metabolism and cancer.
1 Contributions
10 Followers
0 Following

Please sign in or register for FREE to comment